At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 240 enrolled
Drug / intervention
Oxycodone/naloxonedrug
Likely dose
Oxycodone/naloxone 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of TARGIN(R) (Oxycodone/Naloxone) in Korean Patients With Spinal Disorders
In Brief
A Phase 4 clinical trial evaluating Oxycodone/naloxone for Spinal Disorders. Completed, enrolled 240 participants.
Detailed Summary
Study Objectives: 1. Primary objective \- To assess the pain reduction after 8 weeks treatment from baseline (week 0) 2. Secondary objectives * To assess the pain reduction after 4 weeks treatment from baseline (week 0) * To assess the EQ-5D * To assess physician's overall satisfaction * To assess subject's overall satisfaction * To assess safety
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Disorders
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2012
First PostedMar 2013
Primary CompletionApr 2013
Study CompletionJul 2013
TodayJul 2026
First PostedMar 14, 2013
Enrollment StartSep 1, 2012
Primary CompletionApr 1, 2013
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.3 years ago
Interventions
Oxycodone/naloxonedrug
Targin 5mg, 10mg, 20mg up to 40mg b.i.d